CLAIMS

1. The use of tesetaxel in the manufacture of a medicament for the treatment of a cancer in a human patient, wherein:
tesetaxel is to be administered on day 1 of a 21-day cycle; and
1,650 mg/m^2 capecitabine is to be administered daily on days 1-14 of the 21-day cycle.

2. The use of tesetaxel in the manufacture of a medicament for the treatment of a cancer in a human patient, wherein:
tesetaxel is to be administered on day 1 of a 21-day cycle; and
825 mg/m^2 capecitabine is to be administered in 28 doses at twice-daily intervals beginning on day 1 of the 21-day cycle.

3. The use of claim 2, wherein each cycle comprises a first dose of capecitabine to be administered on day 1 of the 21-day cycle and a final 28^{th} dose of capecitabine to be administered on day 15 of the 21-day cycle.

4. The use of any one of claims 1-3, comprising repeating the 21-day cycle at least once.

5. The use of any one of the preceding claims, wherein 18-31 mg/m^2 of tesetaxel is to be administered on day 1 of the 21-day cycle.

6. The use of any one of the preceding claims, wherein 27 mg/m^2 of tesetaxel is to be administered on day 1 of the 21-day cycle.

7. The use of any one of claims 1, 2, and 4-6, wherein capecitabine is to be administered twice daily on days 1-14 of the 21-day cycle.

8. The use of claim 1, wherein 28 doses of 825 mg/m^2 capecitabine is to be administered at twice-daily intervals.

9. The use of any one of the preceding claims, wherein the patient has previously been treated with a taxane.

10. The use of any one of the preceding claims, wherein the cancer is breast cancer.

11. The use of any one of the preceding claims, wherein the cancer is locally advanced or metastatic breast cancer.

12. The use of claim 11, wherein the cancer is locally advanced breast cancer.

13. The use of claim 11, wherein the cancer is metastatic breast cancer.

14. The use of any one of claims 10-13, wherein the breast cancer is hormone receptor positive.

15. The use of any one of claims 10-14, wherein the patient has previously received endocrine therapy.

16. The use of any one of claims 10-15, wherein the breast cancer is estrogen receptor positive.

17. The use of any one of claims 10-16, wherein the breast cancer is progesterone receptor positive.

18. The use of any one of claims 10-17, wherein the breast cancer is HER2-negative.

19. The use of any one of claims 10-17, wherein the breast cancer is hormone receptor positive and HER2-negative.